Targeting RyR

A novel mechanism to correct calcium channel dysfunction

Targeting a fundamental signaling pathway

Decades of foundational research have made it possible to drug ryanodine receptors (RyRs), ion channels that regulate the intracellular flow of calcium in nearly all cell types and are essential for muscle contraction.

We are developing a novel class of therapeutics, called Rycals®, for serious diseases with high unmet need in which ryanodine receptors play a critical role in disease progression.

View our science

Breaking the
cycle of heart failure

Heart failure is a chronic, progressive condition with current treatments aiming to slow decline in cardiac function and manage symptoms. Our lead candidate, ARM210, has the potential to break the cycle of heart failure by addressing an underlying driver of disease progression and by strengthening both cardiac and skeletal muscle cells.

Our solution for heart failure
Back to top